Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection
Summers BB. Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection Drugs Today (Barc) 2018; 54(4):255-268.
Drugs of today (Barcelona, Spain : 1998)
Hepatitis C virus (HCV) is a significant public health burden worldwide, owing in large part to ineffective and poorly tolerated treatments. The antivirals have evolved over time to become more effective and better tolerated with cure rates increasing from an average of 50% to a complete virologic response. This article summarizes the latest Food and Drug Administration (FDA)-approved addition to combination treatment for patients with HCV, voxilaprevir plus sofosbuvir/velpatasvir.
Medical Subject Headings
Antiviral Agents; Carbamates; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Sofosbuvir; Sulfonamides; Treatment Outcome